Editorial Note
Editor-in-Chief
This issue contains two editorial comments on two different and important topics for the practicing nephrologist.
The first is a comment on the latest US K/DOQI Anaemia Guidelines, and summarizes the reasoning behind this update and the implications for the European nephrology community. It was written by three authorities in this field who were involved in the European Best Practice Guidelines on Anaemia and/or in the update of the US guidelines.
The second comment is related to the publication in this issue of two papers on the efficacy and cost-effectiveness of sevelamer in patients with end-stage renal disease. We invited three international experts of the Cochrane Renal Group to put these somewhat controversial papers into perspective.
We hope these editorials and papers will be appreciated by our readership and that they generate some interesting discussion in our correspondence section.
![]()
CiteULike
Connotea
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||